Saltar al contenido
Merck
  • Genetic manipulation of the ghrelin signaling system in male mice reveals bone compartment specificity of acylated and unacylated ghrelin in the regulation of bone remodeling.

Genetic manipulation of the ghrelin signaling system in male mice reveals bone compartment specificity of acylated and unacylated ghrelin in the regulation of bone remodeling.

Endocrinology (2014-07-26)
Patric J D Delhanty, Martijn van der Velde, Bram C J van der Eerden, Yuxiang Sun, Julia M M Geminn, Aart-Jan van der Lely, Roy G Smith, Johannes P T M van Leeuwen
RESUMEN

Ghrelin receptor-deficient (Ghsr-/-) mice that lack acylated ghrelin (AG) signaling retain a metabolic response to unacylated ghrelin (UAG). Recently, we showed that Ghsr-deficiency affects bone metabolism. The aim of this study was to further establish the impact of AG and UAG on bone metabolism. We compared bone metabolism in Ghsr-/- (lacking only AG signaling) and ghrelin-deficient (Ghrl-/-; both AG and UAG deficient) male mice. Ghrl-/- mice had lower cortical bone mass, whereas Ghsr-/- mice had lower trabecular bone mass. This demonstrates bone compartment-specific effects of AG and a role for UAG in bone metabolism. Also, Ghrl-/- but not Ghsr-/- mice had increased bone formation rate and increased osteogenic stem cell numbers in their bone marrow. In ex vivo bone marrow cultures both AG and UAG inhibited osteoblast differentiation. This indicated that bone resorption must be increased in these mice. Accordingly, osteoclastogenesis rate was faster in bone marrow cultures from Ghsr-/- and Ghrl-/- mice, and osteoclast formation was inhibited by AG signaling and partially suppressed by UAG. In osteoblast cultures, AG markedly induced osteoprotegerin gene expression and both peptides reduced RANKL/osteoprotegerin ratio. These data describe unique cell-type specific effects of AG and UAG within a single tissue, supporting a tight and complex control of bone formation and resorption as well as a link between nutrition and bone metabolism. The balance between AG and UAG actions in the bone marrow may lead to bone compartmental-specific effects.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ácido L-ascórbico, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
Ácido L-ascórbico, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
Metilmetacrilato, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
Ácido L-ascórbico, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
Ácido L-ascórbico, reagent grade, crystalline
USP
Ácido L-ascórbico, United States Pharmacopeia (USP) Reference Standard
Supelco
Ácido L-ascórbico, analytical standard
Sigma-Aldrich
Hematoxylin
Sigma-Aldrich
Ácido L-ascórbico, reagent grade
Sigma-Aldrich
Ácido L-ascórbico, meets USP testing specifications
Sigma-Aldrich
Metilmetacrilato, 99%, stabilized
Sigma-Aldrich
Ácido L-ascórbico, 99%
Sigma-Aldrich
Ácido L-ascórbico, FCC, FG
Supelco
Ácido L-ascórbico, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ácido L-ascórbico, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
Ácido L-ascórbico, ACS reagent, ≥99%
Sigma-Aldrich
Hematoxylin, certified by the Biological Stain Commission
Sigma-Aldrich
Ácido L-ascórbico, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe, ≥97% (HPLC)
Ácido L-ascórbico, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ácido L-ascórbico, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
Ácido L-ascórbico, tested according to Ph. Eur.
Amphotericin B, European Pharmacopoeia (EP) Reference Standard
Supelco
Ácido L-ascórbico, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Metilmetacrilato, European Pharmacopoeia (EP) Reference Standard